Talis Biomedical Corporation (TLIS)
NASDAQ: TLIS · IEX Real-Time Price · USD
8.98
+0.03 (0.34%)
May 17, 2024, 4:00 PM EDT - Market closed
Company Description
Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States.
Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.
Talis Biomedical Corporation
Country | United States |
Founded | 2010 |
IPO Date | Feb 12, 2021 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 99 |
CEO | Robert Kelley MBA |
Contact Details
Address: 1100 Island Drive, Suite 101 Redwood City, California 94065 United States | |
Phone | 650-433-3000 |
Website | talisbio.com |
Stock Details
Ticker Symbol | TLIS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001584751 |
CUSIP Number | 87424L108 |
ISIN Number | US87424L2079 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Robert Kelley MBA | Chief Executive Officer and Director |
Dr. Andrew A. Lukowiak Ph.D. | President and Chief Scientific Officer |
Dr. Rustem F. Ismagilov Ph.D. | Co-Founder and Director |
Rebecca Markovich | Interim Chief Financial Officer |
Liang Li Ph.D. | Co-Founder and Director of Technology and Strategy |
Emily Faucette | Senior Vice President of Corporate Communications and Investor Relations |
Jill Green | Senior Vice President of Legal |
Matthew Pepe | Vice President of Human Resource |
Margaret Barrett M.S. | Controller |
Gillian Green | Company Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 8, 2024 | 10-Q | Quarterly Report |
May 3, 2024 | 8-K | Current Report |
Apr 11, 2024 | 8-K | Current Report |
Mar 29, 2024 | EFFECT | Notice of Effectiveness |
Mar 28, 2024 | 10-K | Annual Report |
Mar 26, 2024 | POS AM | Post-Effective amendments for registration statement |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 26, 2024 | 8-K | Current Report |
Nov 14, 2023 | 10-Q | Quarterly Report |
Nov 14, 2023 | 8-K | Current Report |